Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2013
At a glance
- Drugs TC 6987 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Targacept
- 27 Mar 2012 Status changed from active, no longer recruiting to completed, according to a Targacept media release.
- 27 Mar 2012 Primary endpoint 'Fasting-glucose-level' has not been met, according to a Targacept media release.
- 21 Feb 2012 Topline results are expected in the first half of 2012.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History